Search

Jean M Gudas

from Los Angeles, CA
Age ~71
Get Report
Also known as:
Jean Marie Gudas, Gean M Gudas, Jean M Gildas, Jaen Gudas, Jacob Gudas, Johanna Gudas
Phone and address:
13340 Chalon Rd, Los Angeles, CA 90049
Related to:
Nelson Sonia Tario, 65Pauline Gudas, 68Shirley Cardente, 87Juanice Tario, 97Marilyn Tario, 70Kathryn Cardente, 39
Connected to:
Christopher J Gudas, 40Marguerite T Gudat, 70Theresa M Guddahl, 64John A Guddat, 81Jerry L Gudde, 71Jeanne C Guddee, 79Jeff S Gudding, 63Daniel A Gude, 65Erika Gude, 46Felicia R Gude, 54

Jean Gudas Phones & Addresses

  • 13340 Chalon Rd, Los Angeles, CA 90049
  • Brentwood, CA
  • Seattle, WA
  • 36178 Crystal Springs Ct, Newark, CA 94560
  • Pacific Palisades, CA
  • 2822 White Ridge Pl, Thousand Oaks, CA 91362
  • Fremont, CA
  • Stratford, CT
  • Kensington, MD

Work

Company: Imaginab Aug 2012 Position: Vice president research and development

Education

Degree: Doctorates, Doctor of Philosophy School / High School: University of California, Los Angeles Specialities: Genetics, Biology, Microbiology

Skills

Drug Discovery • Drug Development • Biotechnology • Cell • Monoclonal Antibodies

Industries

Biotechnology

Resumes

Resumes

Jean Gudas Photo 1

Vice President Research And Development

View page
Location:
Los Angeles, CA
Industry:
Biotechnology
Work:
Imaginab
Vice President Research and Development
Kite Pharma, Inc.
Senior Director Preclinical Development
Biopharm Strategies
Senior Preclinical Consultant
Agensys, Inc. Jun 2003 - Jun 2010
Senior Director
Abgenix 2000 - 2003
Senior Scientist
Education:
University of California, Los Angeles
Doctorates, Doctor of Philosophy, Genetics, Biology, Microbiology
Skills:
Drug Discovery
Drug Development
Biotechnology
Cell
Monoclonal Antibodies

Publications

Us Patents

Methods For Using Anti-Muc18 Antibodies

View page
US Patent:
7067131, Jun 27, 2006
Filed:
Dec 26, 2002
Appl. No.:
10/330530
Inventors:
Jean Gudas - Los Angeles CA, US
Larry L. Green - San Francisco CA, US
Menashe Bar-Eli - Houston TX, US
Assignee:
Abgenix, Inc. - Fremont CA
International Classification:
A61K 39/395
C07K 16/00
C12P 21/00
C12P 21/04
C12P 21/08
US Classification:
4241421, 4241301, 4241551, 4241561, 4241811, 5303871, 53038815, 53038885, 5303917, 435 696, 800 6
Abstract:
The present invention relates generally to the generation and characterization of anti-MUC18 monoclonal antibodies. The invention further relates to the use of such anti-MUC18 antibodies in the diagnosis and treatment of disorders associated with increased activity of MUC18, in particular, tumors, such as melanomas.

Antibodies Directed To Monocyte Chemo-Attractant Protein-1 (Mcp-1) And Uses Thereof

View page
US Patent:
7202343, Apr 10, 2007
Filed:
Aug 19, 2003
Appl. No.:
10/644277
Inventors:
Jean M. Gudas - Pacific Palisades CA, US
Mary Haak-Frendscho - Newark CA, US
Orit Foord - Foster-City CA, US
Meina L. Liang - Danville CA, US
Kiran Ahluwalia - Fremont CA, US
Sunil Bhakta - Hayward CA, US
Assignee:
Abgenix, Inc. - Fremont CA
International Classification:
C07K 16/00
US Classification:
5303871, 5303879, 514 2, 514 8, 514 12, 4241541, 4241391
Abstract:
Embodiments of the invention described herein relate to antibodies directed to the antigen monocyte chemo-attractant protein-1 (MCP-1) and uses of such antibodies. In particular, in accordance with some embodiments, there are provided fully human monoclonal antibodies directed to the antigen MCP-1. Nucelotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

Nucleic Acid And Corresponding Protein Named 158P1D7 Useful In The Treatment And Detection Of Bladder And Other Cancers

View page
US Patent:
7358353, Apr 15, 2008
Filed:
Feb 10, 2004
Appl. No.:
10/776773
Inventors:
Aya Jakobovits - Beverly Hills CA, US
Robert Kendall Morrison - Santa Monica CA, US
Arthur B. Raitano - Los Angeles CA, US
Pia M. Challita-Eid - Encino CA, US
Juan J. Perez-Villar - Los Angeles CA, US
Karen Jane Meyrick Morrison - Santa Monica CA, US
Mary Faris - Los Angeles CA, US
Jean Gudas - Pacific Palisades CA, US
Steven B. Kanner - Santa Monica CA, US
Assignee:
Agensys, Inc. - Santa Monica CA
International Classification:
C07H 21/00
C07H 5/00
C07H 19/00
C07H 21/02
C08B 37/00
C12N 15/00
US Classification:
536 235, 536 187, 536 221, 536 231, 536 241, 4353201, 530350
Abstract:
A novel gene (designated 158P1D7) and its encoded protein are described. While 158P1D7 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including set forth in Table 1. Consequently, 158P1D7 provides a diagnostic and/or therapeutic target for cancers. The 158P1D7 gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit an immune response.

Antibodies Against Carbonic Anhydrase Ix (Ca Ix) Tumor Antigen

View page
US Patent:
7378091, May 27, 2008
Filed:
Dec 2, 2002
Appl. No.:
10/309762
Inventors:
Jean Gudas - Newark CA, US
Ian Foltz - Vancouver, CA
Masahisa Handa - El Cerrito CA, US
Michael L. Gallo - North Vancouver, CA
Assignee:
Amgen Fremont Inc. - South San Francisco CA
International Classification:
A61K 39/395
C07K 16/18
C07K 16/32
US Classification:
4241301, 4241421, 4241461, 4241781, 4241811, 4241831, 4241381, 5303911, 5303888, 53038821, 5303913, 5303917
Abstract:
The present invention relates generally to the generation and characterization of anti-CA IX monoclonal antibodies. The invention further relates to the use of such anti-CA IX antibodies in the diagnosis and treatment of disorders associated with increased activity of CA IX, in particular, tumors such as colorectal cancer, renal cell carcinoma (RCC), cervical and other cancers of epithelial origin.

Antibodies And Related Molecules That Bind To 161P2F10B Proteins

View page
US Patent:
7427399, Sep 23, 2008
Filed:
Mar 31, 2006
Appl. No.:
11/396178
Inventors:
Aya Jakobovits - Beverly Hills CA, US
Steven B. Kanner - Santa Monica CA, US
Pia M. Challita-Eid - Encino CA, US
Juan J. Perez-Villar - Santa Monica CA, US
Daulet Satpaev - Santa Monica CA, US
Arthur B. Raitano - Los Angeles CA, US
Robert Kendall Morrison - Santa Monica CA, US
Karen Jane Meyrick Morrison - Santa Monica CA, US
Xiao-chi Jia - Los Angeles CA, US
Jean Gudas - Los Angeles CA, US
Assignee:
Agensys, Inc. - Santa Monica CA
International Classification:
C07K 16/30
US Classification:
4241381, 4241301, 4241391, 4241411, 4241421, 5303871, 5303877, 5303881, 435 71
Abstract:
Antibodies and molecules derived therefrom that bind to 161P2F10B protein and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.

Antibodies Directed To Monocyte Chemo-Attractant Protein-1 (Mcp-1) And Uses Thereof

View page
US Patent:
7482434, Jan 27, 2009
Filed:
Dec 19, 2006
Appl. No.:
11/641128
Inventors:
Jean M. Gudas - Pacific Palisades CA, US
Mary Haak-Frendscho - Newark CA, US
Orit Foord - Foster-City CA, US
Meina L. Liang - Danville CA, US
Kiran Ahluwalia - Fremont CA, US
Sunil Bhakta - Hayward CA, US
Assignee:
AstraZeneca AB - Sodertalje
International Classification:
C07K 16/00
A61K 39/395
US Classification:
5303871, 4241301
Abstract:
Embodiments of the invention described herein relate to antibodies directed to the antigen monocyte chemo-attractant protein-1 (MCP-1) and uses of such antibodies. In particular, in accordance with some embodiments, there are provided fully human monoclonal antibodies directed to the antigen MCP-1. Nucelotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

Modified Peptides As Therapeutic Agents

View page
US Patent:
7488590, Feb 10, 2009
Filed:
Aug 18, 2003
Appl. No.:
10/645784
Inventors:
Ulrich Feige - Newbury Park CA, US
Janet C. Cheetham - Montecito CA, US
Thomas Charles Boone - Newbury Park CA, US
Jean Marie Gudas - Thousand Oaks CA, US
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
C12Q 1/68
C12P 21/02
US Classification:
435 697, 435 695, 435 691, 435 911, 530351, 530350, 530324, 536 234
Abstract:
Pharmacologically active compounds are prepared by (a) selecting at least one peptide that modulates the activity of AGP-3, (b) preparing a gene construct that comprises at least one said selected sequence, and (c) expressing the pharmacologically active compound in which an Fc domain is covalently linked to the selected peptide. The pharmacologic agent can be expressed in.

Antibodies And Molecules Derived Therefrom That Bind To Steap-1 Proteins

View page
US Patent:
7494646, Feb 24, 2009
Filed:
Apr 23, 2004
Appl. No.:
10/830899
Inventors:
Aya Jakobovits - Beverly Hills CA, US
Soudabeh Etessami - Tarzana CA, US
Pia M. Challita-Eid - Encino CA, US
Juan J. Perez-Villar - Los Angeles CA, US
Karen J. Morrison - Santa Monica CA, US
Xiao-Chi Jia - Los Angeles CA, US
Mary Faris - Los Angeles CA, US
Jean Gudas - Pacific Palisades CA, US
Arthur B. Raitano - Los Angeles CA, US
Assignee:
Agensys, Inc. - Santa Monica CA
International Classification:
A61K 48/00
US Classification:
4241301, 4241781, 435 71
Abstract:
Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.
Control profile
Jean M Gudas from Los Angeles, CA, age ~71 Get Report